These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 23829929)

  • 1. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges.
    Han EQ; Li XL; Wang CR; Li TF; Han SY
    J Hematol Oncol; 2013 Jul; 6():47. PubMed ID: 23829929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
    Lipowska-Bhalla G; Gilham DE; Hawkins RE; Rothwell DG
    Cancer Immunol Immunother; 2012 Jul; 61(7):953-62. PubMed ID: 22527245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.
    Kim MG; Kim D; Suh SK; Park Z; Choi MJ; Oh YK
    Arch Pharm Res; 2016 Apr; 39(4):437-452. PubMed ID: 26895243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.
    Li K; Lan Y; Wang J; Liu L
    Tumour Biol; 2017 Mar; 39(3):1010428317692229. PubMed ID: 28347250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Armed T cells with CAR for cancer immunotherapy.
    Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
    [No Abstract]   [Full Text] [Related]  

  • 10. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
    Luo C; Wei J; Han W
    Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Strategies for the Treatment of Solid Tumors with CAR-T Cells.
    Zhang H; Ye ZL; Yuan ZG; Luo ZQ; Jin HJ; Qian QJ
    Int J Biol Sci; 2016; 12(6):718-29. PubMed ID: 27194949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.
    Liu D; Tian S; Zhang K; Xiong W; Lubaki NM; Chen Z; Han W
    Protein Cell; 2017 Dec; 8(12):861-877. PubMed ID: 28488245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.
    Curran KJ; Pegram HJ; Brentjens RJ
    J Gene Med; 2012 Jun; 14(6):405-15. PubMed ID: 22262649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
    Jindal V; Arora E; Gupta S
    Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CARTs for Solid Tumors: Feasible or Infeasible?
    Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q
    Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer.
    Zhang Q; Li H; Yang J; Li L; Zhang B; Li J; Zheng J
    Curr Gene Ther; 2013 Feb; 13(1):65-70. PubMed ID: 23256743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
    Harris DT; Kranz DM
    Trends Pharmacol Sci; 2016 Mar; 37(3):220-230. PubMed ID: 26705086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010.
    Ertl HC; Zaia J; Rosenberg SA; June CH; Dotti G; Kahn J; Cooper LJ; Corrigan-Curay J; Strome SE
    Cancer Res; 2011 May; 71(9):3175-81. PubMed ID: 21531763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating cancer with genetically engineered T cells.
    Park TS; Rosenberg SA; Morgan RA
    Trends Biotechnol; 2011 Nov; 29(11):550-7. PubMed ID: 21663987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor-redirected T cells return to the bench.
    Geldres C; Savoldo B; Dotti G
    Semin Immunol; 2016 Feb; 28(1):3-9. PubMed ID: 26797495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.